These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26083655)

  • 1. Disruption of tubular Flcn expression as a mouse model for renal tumor induction.
    Chen J; Huang D; Rubera I; Futami K; Wang P; Zickert P; Khoo SK; Dykema K; Zhao P; Petillo D; Cao B; Zhang Z; Si S; Schoen SR; Yang XJ; Zhou M; Xiao GQ; Wu G; Nordenskjöld M; Tauc M; Williams BO; Furge KA; Teh BT
    Kidney Int; 2015 Nov; 88(5):1057-69. PubMed ID: 26083655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
    Hasumi H; Baba M; Hasumi Y; Furuya M; Yao M
    Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
    Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
    Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.
    Hudon V; Sabourin S; Dydensborg AB; Kottis V; Ghazi A; Paquet M; Crosby K; Pomerleau V; Uetani N; Pause A
    J Med Genet; 2010 Mar; 47(3):182-9. PubMed ID: 19843504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
    Baba M; Furihata M; Hong SB; Tessarollo L; Haines DC; Southon E; Patel V; Igarashi P; Alvord WG; Leighty R; Yao M; Bernardo M; Ileva L; Choyke P; Warren MB; Zbar B; Linehan WM; Schmidt LS
    J Natl Cancer Inst; 2008 Jan; 100(2):140-54. PubMed ID: 18182616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
    Chen J; Futami K; Petillo D; Peng J; Wang P; Knol J; Li Y; Khoo SK; Huang D; Qian CN; Zhao P; Dykema K; Zhang R; Cao B; Yang XJ; Furge K; Williams BO; Teh BT
    PLoS One; 2008; 3(10):e3581. PubMed ID: 18974783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression.
    Nagashima K; Fukushima H; Shimizu K; Yamada A; Hidaka M; Hasumi H; Ikebe T; Fukumoto S; Okabe K; Inuzuka H
    Oncotarget; 2017 Feb; 8(6):9947-9960. PubMed ID: 28039480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn.
    Hasumi H; Baba M; Hasumi Y; Lang M; Huang Y; Oh HF; Matsuo M; Merino MJ; Yao M; Ito Y; Furuya M; Iribe Y; Kodama T; Southon E; Tessarollo L; Nagashima K; Haines DC; Linehan WM; Schmidt LS
    Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1624-31. PubMed ID: 25775561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of Birt-Hogg-Dubé syndrome implying reduced or no wild-type folliculin without mutated protein is pathogenic.
    Enomoto Y; Namba Y; Hoshika Y; Komemushi Y; Mitani K; Kume H; Kobayashi E; Miyama Y; Homma Y; Ushiku T; Seyama K
    Eur J Med Genet; 2020 Apr; 63(4):103820. PubMed ID: 31778855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folliculin deficient renal cancer cells show higher radiosensitivity through autophagic cell death.
    Zhang Q; Si S; Schoen S; Jin XB; Chen J; Wu G
    J Urol; 2014 Jun; 191(6):1880-8. PubMed ID: 24434776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
    Lu X; Wei W; Fenton J; Nahorski MS; Rabai E; Reiman A; Seabra L; Nagy Z; Latif F; Maher ER
    Mol Cancer Ther; 2011 Jan; 10(1):80-9. PubMed ID: 21220493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.
    Hong SB; Oh H; Valera VA; Stull J; Ngo DT; Baba M; Merino MJ; Linehan WM; Schmidt LS
    Mol Cancer; 2010 Jun; 9():160. PubMed ID: 20573232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical characterization of renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Iribe Y; Kuroda N; Nagashima Y; Yao M; Tanaka R; Gotoda H; Kawakami F; Imamura Y; Nakamura Y; Ando M; Araki A; Matsushima J; Nakatani Y; Furuya M
    Pathol Int; 2015 Mar; 65(3):126-32. PubMed ID: 25597876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.
    Hasumi Y; Baba M; Ajima R; Hasumi H; Valera VA; Klein ME; Haines DC; Merino MJ; Hong SB; Yamaguchi TP; Schmidt LS; Linehan WM
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18722-7. PubMed ID: 19850877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).
    Lu X; Boora U; Seabra L; Rabai EM; Fenton J; Reiman A; Nagy Z; Maher ER
    Oncogene; 2014 Feb; 33(8):956-65. PubMed ID: 23416984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer.
    Bartram MP; Mishra T; Reintjes N; Fabretti F; Gharbi H; Adam AC; Göbel H; Franke M; Schermer B; Haneder S; Benzing T; Beck BB; Müller RU
    BMC Med Genet; 2017 May; 18(1):53. PubMed ID: 28499369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein.
    Takagi Y; Kobayashi T; Shiono M; Wang L; Piao X; Sun G; Zhang D; Abe M; Hagiwara Y; Takahashi K; Hino O
    Oncogene; 2008 Sep; 27(40):5339-47. PubMed ID: 18663353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-Wide Uniparental Disomy and Copy Number Variations in Renal Cell Carcinomas Associated with Birt-Hogg-Dubé Syndrome.
    Iribe Y; Yao M; Tanaka R; Kuroda N; Nagashima Y; Nakatani Y; Furuya M
    Am J Pathol; 2016 Feb; 186(2):337-46. PubMed ID: 26776076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E; Laubscher D; Hopfer H; Streit M; Matyas G
    Fam Cancer; 2016 Jan; 15(1):127-32. PubMed ID: 26342594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.